China HeadAche DIsorders RegiStry

Key facts

Sponsor

Beijing Tiantan Hospital

Intervention

Medicine Overuse Headache/New Daily Persistent Headache(behavioral)

Enrollment

10000 target

Eligibility

12 years · All sexes

Timeline

2022 – 2032

Study locations (20)

• Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
• Beijing Chaoyang Hospital, Beijing, Beijing Municipality, China
• Chongqing People's Hospital, Chongqing, Chongqing Municipality, China
• Fujian Provincial Hospital, Fuzhou, Fujian, China
• The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China
• The First People's Hospital of Zunyi, Zunyi, Guizhou, China
• Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine, Qionghai, Hainan, China
• Zhangjiakou First Hospital, Zhangjiakou, Hebei, China
• Luohe Central Hospital, Luohe, Henan, China
• Luoyang Central Hospital, Luoyang, Henan, China
• The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
• The 7th People's Hospital of Zhengzhou, Zhengzhou, Henan, China
• Changzhou First People's Hospital, Changzhou, Jiangsu, China
• Jiujiang First People's Hospital, Jiujiang, Jiangxi, China
• The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.